FDA Approves Dupixent to Treat Eczema

Share this content:
FDA Approves Dupixent to Treat Eczema
FDA Approves Dupixent to Treat Eczema

WEDNESDAY, March 29, 2017 (HealthDay News) -- Dupixent (dupilumab) has been approved by the U.S. Food and Drug Administration to treat moderate-to-severe eczema that isn't well controlled by topical medication.

The active ingredient in Dupixent is an antibody (dupilumab) that binds to a protein (interleukin-4 receptor alpha subunit) that causes inflammation, and is administered subcutaneously. Its effectiveness was evaluated in clinical studies involving 2,119 patients for whom topical medication hadn't worked. Overall, participants who received Dupixent achieved clear or almost clear skin and a reduction in itch after 16 weeks of treatment.

The most common side effects included injection-site reactions, cold sores, and eye inflammation. More serious adverse effects included severe allergic reactions, conjunctivitis, and keratitis.

"FDA's approval of Dupixent demonstrates our commitment to approving new and innovative therapies for patients with skin disease," Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA's Center for Drug Evaluation and Research, said in a statement. "Eczema can cause significant skin irritation and discomfort for patients, so it is important to have a variety of treatment options available to patients, including those patients whose disease is not controlled by topical therapies."

The FDA granted approval of Dupixent to Regeneron Pharmaceuticals.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Gender Nonconformity Linked to Students' Mental Distress

Gender Nonconformity Linked to Students' Mental Distress

For male students, gender nonconformity strongly associated with substance use

Participation Up With Online Diabetes Prevention Program

Participation Up With Online Diabetes Prevention Program

But weight loss no different for online, in-person DPP for obese/overweight veterans with prediabetes

Net Benefit of Anticoagulants for A-Fib Varies With Stroke Rate

Net Benefit of Anticoagulants for A-Fib Varies With ...

Benefit of warfarin anticoagulation varies with varying published stroke rates

is free, fast, and customized just for you!




Already a member?

Sign In Now »